Products
Ongoing projects.
The source site lists VesaPro, VesaSomes, VesaPerio, VesaGro, RegenBalm, QBio Elixir, and QBio Grow. Each formula is described as created using proprietary processing methods in an ISO Class 3 laboratory.
Research & technology
Precision at the cellular level.
Human umbilical cord and amniotic membrane-derived biomolecules, developed under controlled laboratory standards.
01 / Active Lab
Research, sourcing, and processing.
Active Lab is described by VivuraCell's source materials as an FDA-registered 361 tissue establishment facility dedicated to developing human umbilical cord and amniotic membrane-derived biomolecules.
The source website states that it partners with FDA-registered and AABB-accredited cord banks and sources tissue from live, full-term, scheduled C-section births in U.S. hospitals. Each donor undergoes comprehensive screening and testing to support tissue eligibility and compliance.
02 / Manufacturing overview
What we manufacture
Cell-derived biomolecules under controlled conditions.
The supplied materials state that products are derived from human umbilical cord and amniotic membrane tissues.
They contain a diverse array of naturally occurring biomolecules, including exosomes, proteins, peptides, growth factors, and other bioactive molecules.
These components are preserved and manufactured under strict environmental and process controls to support quality, reproducibility, and safety.
Integrity
Meeting standards.
The source website states that products are processed in compliance with FDA Section 361 of the Public Health Service Act and 21 CFR Part 1271 for Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), along with cGMP standards.
Clinical reliability
Quality control.
The ISO Class 3 laboratory is described as operating under strict quality-control and sterility guidelines. Minimally manipulative techniques are used to preserve the bioactivity and natural integrity of cell-derived biomolecules.
VivuraCell states that this commitment supports batch-to-batch consistency, clinical reliability, and optimal patient outcomes.
03 / Supplied laboratory data
Composition & particle distribution
Source data prepared for review.
Values below reproduce the supplied laboratory documents. Units, product names, dates, and source labels are preserved as provided.
Product portfolio
VesaShot · VesaFlow · VesaPro
| Biomolecule | VesaShot | VesaFlow | VesaPro |
|---|---|---|---|
| ECM scaffold | |||
| Collagen | 142000 | 3000 | 151950 |
| Elastin | 11360 | 30000 | 40428 |
| Fibronectin | 284000 | 11100000 | 10843200 |
| Hyaluronic Acid | <1000 | 4800 | 5610 |
| Fetuin - A | 5396000 | 24000 | 5893800 |
| Serpin A4 | 142000 | 54000 | 200400 |
| Cell-cell and cell-ECM interaction | |||
| Thrombospondin - 2 | <1000 | 3000 | 3900 |
| Adhesion G Protein | 7100 | <1000 | 8405 |
| ICAM 1 | 11360 | <1000 | 12878 |
| Immune and inflammatory response | |||
| Complement C5 | 11360 | 30000 | 40428 |
| Galectin - 9 | <1000 | 4800 | 5610 |
| IL1RN | <1000 | 6000 | 6750 |
| Cell survival, division, differentiation, and migration | |||
| Fibroblast Growth Factors | 1420 | <1000 | 2441 |
| IGFBP 3 | 7100 | 4200000 | 3997455 |
| IGFBP 6 | 142000 | <1000 | 150050 |
| IGFBP 1 | 426000 | 120000 | 561300 |
| EFG R | <1000 | 4800 | 5610 |
Raw data identified in the supplied document as obtained from the Proteomics Core Division at UT Southwestern Medical Center, dated January 24, 2024.
Composition portfolio
RegenBalm · VesaSomes · VesaGrow
| Biomolecule | RegenBalm | VesaSomes | VesaGrow |
|---|---|---|---|
| ECM scaffold | |||
| Collagen | 37.99 | 29514 | 4873 |
| Elastin | 10.10 | 10673 | 857 |
| Fibronectin | 2,710.80 | 3460320 | 690885 |
| Hyaluronic Acid | 1.40 | 1695 | 216 |
| Fetuin - A | 1,473.45 | 1754859 | 499228 |
| Serpin A4 | 50.10 | 51493 | 9036 |
| Cell-cell and cell-ECM interaction | |||
| Thrombospondin - 2 | <1.00 | 1084 | 284 |
| Adhesion G Protein | 2.10 | 2214 | 552 |
| ICAM 1 | 3.22 | 2600 | 410 |
| Immune and inflammatory response | |||
| Complement C5 | 10.11 | 11108 | 956 |
| Galectin - 9 | 1.40 | 1684 | 484 |
| IL1RN | 1.69 | 2087 | 559 |
| Cell survival, division, differentiation, and migration | |||
| Fibroblast Growth Factors | <1.00 | 533 | 118 |
| IGFBP 3 | 999.36 | 1155205 | 216904 |
| IGFBP 6 | 37.51 | 34606 | 6371 |
| IGFBP 1 | 140.32 | 170467 | 24071 |
| EFG R | 1.40 | 1692 | 399 |
Raw data identified in the supplied document as obtained from the Proteomics Core Division at UT Southwestern Medical Center, dated January 24, 2024.
DLS nanoparticle counter
Fifteen-sample particle-size datasets.
Counts are reported in ×10^9 across 0-30 nm, 30-150 nm, and greater-than-150 nm ranges. The supplied documents identify the 30-150 nm range as the exosome-size range.
VesaGro / ActiveMediaAverage: 0.164 / 4.11 / 1.34
| Sample | 0-30 nm | 30-150 nm | >150 nm |
|---|---|---|---|
| 1 | 0.094 | 5.10 | 1.7 |
| 2 | 0.104 | 4.30 | 0.86 |
| 3 | 0.114 | 2.61 | 1.74 |
| 4 | 0.124 | 4.40 | 1.76 |
| 5 | 0.134 | 2.67 | 1.78 |
| 6 | 0.144 | 5.40 | 1.8 |
| 7 | 0.154 | 2.73 | 0.91 |
| 8 | 0.164 | 4.60 | 0.92 |
| 9 | 0.174 | 2.79 | 0.93 |
| 10 | 0.184 | 3.76 | 1.88 |
| 11 | 0.194 | 3.80 | 1.9 |
| 12 | 0.204 | 4.80 | 0.96 |
| 13 | 0.214 | 2.91 | 0.97 |
| 14 | 0.224 | 5.88 | 0.98 |
| 15 | 0.234 | 5.94 | 0.99 |
| Average | 0.164 | 4.11 | 1.34 |
VesaSomes / ActiveSomesAverage: 0.217 / 9.214 / 0.530
| Sample | 0-30 nm | 30-150 nm | >150 nm |
|---|---|---|---|
| 1 | 0.11 | 8.945 | 0.612 |
| 2 | 0.217 | 9.127 | 0.45 |
| 3 | 0.246 | 9.356 | 0.674 |
| 4 | 0.31 | 9.214 | 0.539 |
| 5 | 0.174 | 9.001 | 0.563 |
| 6 | 0.201 | 9.478 | 0.348 |
| 7 | 0.289 | 9.342 | 0.576 |
| 8 | 0.188 | 8.901 | 0.501 |
| 9 | 0.23 | 9.134 | 0.462 |
| 10 | 0.124 | 9.289 | 0.524 |
| 11 | 0.143 | 9.487 | 0.511 |
| 12 | 0.255 | 8.998 | 0.59 |
| 13 | 0.347 | 9.204 | 0.586 |
| 14 | 0.096 | 9.321 | 0.324 |
| 15 | 0.319 | 9.412 | 0.685 |
| Average | 0.217 | 9.214 | 0.530 |
Review note: the supplied VesaPerio DLS PDF is identical to the supplied VesaSomes DLS PDF and is labeled ActiveSomes. It is provided below without changing the scientific chart or assigning it different results. The supplied composition document also uses the product label VesaGrow; that source naming is preserved here.
PDF
Product Portfolio 1VesaShot, VesaFlow, and VesaPro
↗PDFProduct Portfolio 2RegenBalm, VesaSomes, and VesaGrow
↗PDFVesaGro DLSNanoparticle size distribution
↗PDFVesaPerio DLSSupplied file - see review note
↗PDFVesaSomes DLSNanoparticle size distribution
↗DLS documents identify raw data from the Proteomics Core Division at UT Arlington, dated September 10, 2024. All five downloads use the supplied transparent VivuraCell logo.
Platform characteristics
01
Exosomes and biomolecules from umbilical cord and amniotic membrane
02
Sourced from healthy, full-term, scheduled C-section births
03
Clinical-grade, lyophilized cosmetic products
04
Patent-pending technology
05
Easy-to-use, all-in-one kit
06
Made in the USA
Regulatory and laboratory claims above are reproduced from the VivuraCell source materials and should be confirmed by the business before public launch.
Explore the formulations